Cryoport Community

NasdaqCM:CYRX Community

1 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 9 Analysts

New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply

Key Takeaways Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth. New cryopreservation solutions and facilities, along with improved logistics, are expected to enhance market reach and contribute to long-term revenue growth.

US$11.28

FV

50.2% undervalued

2.91%

Revenue growth p.a.

0

0

1

6 days ago